Effects of Pulmonary Rehabilitation on Skeletal Muscle in COPD Patients
Effects of Pulmonary Rehabilitation on Skeletal Muscle Morphology and Metabolism in PiMM vs. PiZZ COPD Patients
In a former study, the investigator observed significant differences in the response to pulmonary rehabilitation between COPD patients with the "normal" genetic variant of alpha-1 antitrypsin (PiMM) and those with a homozygous deficient variant (PiZZ) (Jarosch et al., 2016, DOI: 10.1159/000449509). PiZZ COPD patients showed less improvement in exercise capacity compared to PiMM patients. This latter finding was mirrored by an increase of oxidative myofiber type I proportion - that is important for aerobic exercises in daily life - in PiMM but not PiZZ patients.
Based on this finding of impaired skeletal muscle adaptation, the aim of this study is to compare the effects of pulmonary rehabilitation including exercise training on a) specific enzymes of energy metabolism reflecting the oxidative capacity of the skeletal muscle and b) the analogue gene expression of these oxidative enzymes in a cohort of PiMM and PiZZ COPD patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Inga Jarosch
- Phone Number: 1730 +49865293
- Email: ijarosch@schoen-kliniken.de
Study Locations
-
-
-
Schönau Am Königssee, Germany, 83471
- Recruiting
- Schoen Klinik Berchtesgadener Land
-
Contact:
- Inga Jarosch
- Phone Number: 0049-8652-931730
- Email: ijarosch@schoen-kliniken.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic obstructive pulmonary disease
- phenotype PiMM or PiZZ
- written informed consent
Exclusion Criteria:
- any comorbidities that prevent patients from participating in an exercise Training program
- necessity of anticoagulant therapy
- other genetic variants of alpha-1 antitrypsin than PiMM or PiZZ
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: PiMM patients
COPD patients with the Alpha-1 antitrypsin genetic variant "PiMM" (Smoking-related COPD)
|
3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
|
|
EXPERIMENTAL: PiZZ patients
COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
|
3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endurance time
Time Frame: 3 weeks
|
Will be measured during a constant work rate cycling test
|
3 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Myofibre type I Distribution
Time Frame: 3 weeks
|
Skeletal muscle sample will be taken from the M.vastus lateralis via Bergström muscle biopsy needle
|
3 weeks
|
|
Capillary to fibre ratio
Time Frame: 3 weeks
|
Skeletal muscle sample will be taken from the M.vastus lateralis via Bergström muscle biopsy needle
|
3 weeks
|
|
muscle strength
Time Frame: 3 weeks
|
strength test in the right knee Extensor and flexor
|
3 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Klaus Kenn, Prof., Department of respiratory medicine, Schoen Klinik Berchtesgadener Land
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAT 2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.